identification of modifiable factors that alter glucose metabolism in this high-risk population is extremely important.
Sleep may be one such factor: poor sleep health, including insufficient and disrupted sleep, has significant negative consequences, including cognitive impairment, poor emotional functioning, and physiological dysfunction. [6] [7] [8] [9] An increasing number of studies also link poor sleep with insulin resistance. [10] [11] [12] Patients with CF have greater objective and subjective sleep problems and are at risk for sleep loss due to both illness symptoms (eg, nighttime cough) and treatments (eg, nocturnal tube feedings, early awakenings for treatments). 13, 14 Children with CF report poorer sleep quality, more sleep disturbances, and evidence of reduced sleep efficiency (SE) on objective measures compared to children without CF. [13] [14] [15] [16] [17] Additionally, over 1/3 of participants in a study of children and teens with CF reported symptoms of insomnia including difficulty falling asleep and maintaining sleep, while nearly 75% endorsed excessive daytime sleepiness. 15 Moreover, some studies, though not all, 17 have found an association between poor sleep health and poor lung function in youth with CF. [14] [15] [16] Prior studies have also found a link between short sleep duration and reduced insulin sensitivity (IS) in otherwise healthy adolescents 12, 18, 19 . However, only one study has previously examined the The goal of the current study was to examine the relationship between objectively measured sleep, using actigraphy in the home environment, and glucose metabolism, using both CGM in the home environment as well as fasting measures of IS, in a sample of adolescents with CF.
2 | METHODS
| Participants
A subset of participants from a larger cross-sectional study examining CGM in CF youth (ClinicalTrials.gov #NCT02211235) underwent sleep monitoring with actigraphy. Included in this study were 43 participants with previously confirmed CF and 11 healthy controls with available actigraphy data. See Figure 1 for a flow diagram of study participants. All participants were between the ages of 10 to 19 years, based on the World Health Organization definition of adolescence, 21 and at baseline health (eg, no illness exacerbation) at enrollment. 
| Procedures
Participants were asked to fast for 8 hours prior to the morning study visit. Anthropometrics were obtained using standardized procedures.
Weight was measured with participants dressed in light clothing to the nearest 0.1 kg using a digital scale. Height was measured to the nearest 0.5 cm using a stadiometer. Child body mass index (BMI) percentile was calculated using the Centers for Disease Control & Prevention protocol. 22 Physical exam was performed and Tanner staging was completed by a pediatric endocrinologist. Baseline lung function data were collected for CF adolescents from their most recent pulmonary clinic visit within 3 months of study participation.
Fasting labs and an OGTT were performed. CF participants on insulin were asked to hold long-acting insulin for 24 hours and shortacting insulin for 4 hours prior to the study visit. Fasting labs included glucose, insulin, and C-peptide. In addition, hemoglobin A1c (HbA1c) and a 2-hour OGTT were obtained to rule out exclusionary criteria (pre-diabetes and diabetes) in the healthy control participants, and to classify participants with CF into categories based on glycemic status:
Normal Glycemia (fasting plasma glucose <100 mg/dL, 1 hour glucose <200 mg/dL, and 2 hours glucose <140 mg/dL), abnormal glycemia (fasting plasma glucose 100-125 mg/dL, 1 hour glucose >200 mg/dL, and/or 2 hours glucose of 140-199 mg/dL), and CFRD (fasting plasma glucose ≥126 mg/dL and/or 2 hours glucose ≥200 mg/dL). After return of the CGM, reports were generated for each partici- to capture typical sleep in the home setting. Actigraphy has been widely used in pediatric sleep research 30 and has been previously used in research with CF patients. 14, 16, 17 Participants also completed a sleep diary reporting their bedtimes and wake times to facilitate accurate scoring of sleep-wake episodes. 31 Total sleep duration, sleep onset latency (SOL; time to fall asleep), wake after sleep onset (WASO; minutes of wake time after initial sleep onset) and SE (percent time asleep out of total time in bed) were calculated using Actiware Sleep v6 software using standard scoring rules (Phillips Respironics, Pittsburgh, Pennsylvania). 31 
| Measures

| Laboratory analyses
Glucose was measured by hexokinase ultraviolet (UV) methodology, with a sensitivity of 10 mg/dL. Insulin was measured by chemilumenescense immunoassay (Beckman Coulter, Brea, California), with a sensitivity of 0.5 uIU/mL. C-peptide was measured using an ELISA kit 
| Statistical analyses
Descriptive statistics for demographic and clinical variables were calculated for all CF participants, CF participants by glycemic status, and for healthy controls. All variables were assessed for normality and non-parametric tests were used when indicated. Two-sample independent t-tests were used to test the differences between actigraphy outcomes in CF vs control participants. ANOVA was used to test the differences between actigraphy outcomes and the four categories of participants. Tukey's honestly significant difference was used for post-hoc testing. Spearman's rank correlation coefficients were used to test for correlations between actigraphy, CGM, and IS measures.
All hypothesis tests were two-sided with significance set at P < 0.05. SAS version 9.4 was used to calculate sleep midpoint. R version 3.1.1 software (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org) was utilized for the rest of the analysis.
3 | RESULTS
| Participant characteristics
Participant descriptive statistics are reported in Table 1 . There were no significant differences in age, sex, ethnicity, BMI, nor Tanner stage among the groups. As expected, HbA1c was lower in control participants compared to CF participants with OGTT-determined abnormal glycemia and CFRD but not those CF participants with OGTTdetermined normal glycemia (P < 0.001). There were no significant differences in lung function among the CF groups and notably, the overall CF cohort had relatively good lung function with a mean forced expiratory volume at 1 second (FEV 1 ) of 94.8%.
Fasting estimates of IS are presented in Table 1 . Participants with CF had higher 1/insulin, glucose/insulin, 1/C-peptide, and glucose/C-peptide compared to healthy control participants (P < 0.05). Post-hoc testing showed that adolescents with CFRD also had higher 1/C-peptide and glucose/C-peptide compared to healthy controls. No significant differences in HOMA-IR were found between CF participants and healthy controls. No significant differences in IS estimates were found among the CF groups.
Sleep data from actigraphy monitoring for the sample are presented in Table 2 . Participants with CF, when compared to healthy controls, had longer SOL (15.7 vs 9.1 minute; P = 0.02), and a trend toward lower SE (82.6% vs 86.5%; P = 0.05) and higher WASO (71.3 vs 52.8 minutes; P = 0.06). There were no differences, however, in actigraphy findings among the CF groups when categorized by OGTT glycemic status. Of note, there was no difference in time of year (ie, school year vs holidays) during which CF adolescents and healthy controls participated in the study.
CGM findings for the cohort are presented in Table 3 . Participants with CF had higher average glucose, SD, peak glucose, %time over 120, 140, and 200 mg/dL and %time under 60 mg/dL on CGM compared to healthy controls (P < 0.05). As expected, post-hoc comparison testing showed that CF adolescents with OGTT-determined abnormal glycemia and CFRD had greater sensor glucose peak, SD, and %time >120 mg/dL than controls. Adolescents with CFRD also had more %time >140 mg/dL than controls.
| Sleep and CGM
Correlations between actigraphy and CGM measures were examined (Table 4) . In healthy controls, longer total sleep time (TST) was associated with less %time <70 mg/dL (r = −0.64, P = 0.04) and longer SOL correlated with higher daytime minimum sensor glucose (r = 0.67, P = 0.03). In all CF participants, longer TST was significantly associated with lower daytime minimum sensor glucoses (r = −0.35, P = 0.03) and greater SE was significantly associated with lower minimum sensor glucoses (r = −0.34, P = 0.03) and lower daytime minimum sensor glucoses (r = −0.38, P = 0.02). No other significant relationships were found between the remaining actigraphy and CGM measures.
| Sleep and insulin sensitivity
The relationships between actigraphy and IS estimates were assessed in each group (Table 5) 
| Sleep and lung functioning
Lung function in this CF cohort as reflected by FEV 1 % (94.8% AE 15%) and forced vital capacity (FVC)% (102.6% AE 15%) was good overall, and did not differ significantly by CF group. No significant association was found between FEV 1 nor FVC and any actigraphy variable in the CF cohort.
| DISCUSSION
To our knowledge, this is the first study examining CGM and sleep in adolescents with CF, and only the second study to examine the relationship between IS and sleep in this population. Similar to previous studies, we found that adolescents with CF had more sleep disruption than healthy controls as reflected by greater onset latency, and a trend toward lower SE and higher WASO. The National Sleep Foundation report on sleep quality 32 states that SOL ≤15 minutes, SE ≥85%, and WASO ≤20 minutes are indicative of good sleep quality. In our sample, while our healthy control adolescents had average onset latency and SE within normal limits, the overall group of CF participants fell below these cutoffs, indicating clinically significant deficiencies in sleep quality. Both healthy controls and adolescents with CF in this cohort had an average WASO indicative of poor sleep quality, however WASO tends to be overestimated with actigraphy Abbreviations: BMI, body mass index; CF, cystic fibrosis; CFRD, cystic fibrosis-related diabetes; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 second; HbA1c, hemoglobin A1c; HOMA-IR, homeostatic model assessment-insulin resistance; N/A, not applicable. HbA1c differed between controls and CF abnormal glycemia and CFRD; HOMA-IR differed between controls and CF normal glycemia; 1/insulin, glucose/insulin, 1/C-peptide, and glucose/ C-peptide all differed between healthy controls and all patients with CF; 1/C-peptide and glucose/C-peptide differed between controls and CFRD. *P < 0.001; † P < 0.05. with adolescents who are chronically sleep deprived. 36 As expected, the overall group of adolescents with CF, including those with CF abnormal glycemia and CFRD, had more hyperglycemia, glucose variability, and hypoglycemia on CGM than healthy controls.
While no CGM differences were found between healthy controls and CF adolescents with normal glycemia in this cohort, we have previously found statistically significant differences in CGM variables between these two groups when larger sample sizes were compared. 37 In CF adolescents, higher minimum sensor glucose values correlated with longer SOL, decreased TST and decreased SE. This higher minimum sensor glucose may reflect increased hepatic glucose output (reflective of increased insulin resistance) or simply increased snacking into the early evening associated with a later sleep time. Prior research has shown that adults who are late sleepers consume more calories late at night. 38 Notably, in this cohort, although CF adolescents had more hypoglycemia measured by CGM time spent <60 mg/ dL and more glucose variability as measured by CGM SD than healthy Abbreviation: CF, cystic fibrosis. *P < 0.001; † P < 0.05; indicates significant difference between healthy controls and all patients with CF. which may explain the significant outcomes detected with fasting C-peptide, but not insulin.
The current study was limited by several factors, including relatively small sample size, particularly for CF subgroups, which may impact reliability of correlational analyses. Healthy controls were lean youth without any reported medical problems; however, participants were not evaluated for sleep disorders, such as OSA, or medications or habits that may impact sleep (eg, antihistamines, caffeine intake, media usage). Actigraphy was an optional component of the larger study from which this sample was derived, thus the current sample may not be fully representative as the participants who agreed to actigraphy may have different sleep patterns from those who did not agree. Moreover, the participants with CF in this study had relatively good lung function (FVC and FEV 1 ), reflective of the age-matched population at our CF center, and findings may be different in CF individuals with a greater degree of pulmonary dysfunction. As the primary pathogenesis leading to dysglycemia in CF is insulin insufficiency, interpretation of fasting estimates of IS in the CF cohort may be confounded by the presence of both abnormal insulin secretion and insulin resistance. While there is no consensus that particular fasting estimates of IS perform more strongly than others, those measures that include both insulin (or C-peptide) and glucose allow assessment of glycemia relative to insulin secretion. Future studies should include stimulated measures of IS or secretion such as the gold standard hyperinsulinemic-euglycemic clamp to verify our findings. In contrast, while PSG is considered a gold standard measure of sleep, actigraphy, as utilized in the current study, is advantageous compared to a single night of PSG as it assesses typical sleep in the home environment over a longer period, and allowed us to measure sleep concurrent with CGM.
Despite these limitations, ours is the first study to look at the relationship between CGM, fasting IS estimates, and actigraphy-measured sleep in adolescents with CF. Multiple comparisons were made without adjustment, thus these results should be considered hypothesis generating. Compared to the limited prior research, our study had a larger sample size and we were able to directly compare participants with CF with normal glycemic status, abnormal glycemia, and CFRD, with healthy controls. Untreated impairments in glucose metabolism can contribute to morbidity and mortality. Thus, identifying factors that may contribute to glucose metabolism in this vulnerable population is important. This study provides preliminary evidence that sleep may be one such variable.
